WO2009007724A3 - Diagnosis and treatment of abnormal blood conditions - Google Patents

Diagnosis and treatment of abnormal blood conditions Download PDF

Info

Publication number
WO2009007724A3
WO2009007724A3 PCT/GB2008/002364 GB2008002364W WO2009007724A3 WO 2009007724 A3 WO2009007724 A3 WO 2009007724A3 GB 2008002364 W GB2008002364 W GB 2008002364W WO 2009007724 A3 WO2009007724 A3 WO 2009007724A3
Authority
WO
WIPO (PCT)
Prior art keywords
abnormal blood
treatment
platelet activation
diagnosis
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2008/002364
Other languages
French (fr)
Other versions
WO2009007724A2 (en
Inventor
Willem Ouwehand
Alison Helena Goodall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EUROPEAN CARDIOVASCULAR GENETICS FOUNDATION
EUROP CARDIOVASCULAR GENETICS
Original Assignee
EUROPEAN CARDIOVASCULAR GENETICS FOUNDATION
EUROP CARDIOVASCULAR GENETICS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EUROPEAN CARDIOVASCULAR GENETICS FOUNDATION, EUROP CARDIOVASCULAR GENETICS filed Critical EUROPEAN CARDIOVASCULAR GENETICS FOUNDATION
Publication of WO2009007724A2 publication Critical patent/WO2009007724A2/en
Publication of WO2009007724A3 publication Critical patent/WO2009007724A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Methods for diagnosing whether a subject has, or is at risk of, an abnormal blood condition are described. The methods comprise determining the expression level of a gene specifically associated with adenosine-di-phosphate (ADP)-stimulated platelet activation, collagen-related peptide (CRP)-stimulated platelet activation, or ADP- and CRP-stimulated platelet activation in a biological sample obtained from the subject. Methods for identifying potential therapeutic agents for the treatment of abnormal blood conditions are also described.
PCT/GB2008/002364 2007-07-10 2008-07-10 Diagnosis and treatment of abnormal blood conditions Ceased WO2009007724A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0713363.0 2007-07-10
GBGB0713363.0A GB0713363D0 (en) 2007-07-10 2007-07-10 Diagnosis and treatment of abnormal blood conditions

Publications (2)

Publication Number Publication Date
WO2009007724A2 WO2009007724A2 (en) 2009-01-15
WO2009007724A3 true WO2009007724A3 (en) 2009-03-26

Family

ID=38461326

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/002364 Ceased WO2009007724A2 (en) 2007-07-10 2008-07-10 Diagnosis and treatment of abnormal blood conditions

Country Status (2)

Country Link
GB (1) GB0713363D0 (en)
WO (1) WO2009007724A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112877418A (en) * 2021-01-11 2021-06-01 丰能医药科技（上海）有限责任公司 Product for detecting vascular permeability and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040067903A1 (en) * 2000-08-02 2004-04-08 Alison Williams-Gagnon Nucleic acids encoding a novel regulator of g protein signaling, rgs18, and uses thereof
US20040170624A1 (en) * 2001-01-23 2004-09-02 Bernhard Nieswandt Medicament for the protection against thrombotic diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040067903A1 (en) * 2000-08-02 2004-04-08 Alison Williams-Gagnon Nucleic acids encoding a novel regulator of g protein signaling, rgs18, and uses thereof
US20040170624A1 (en) * 2001-01-23 2004-09-02 Bernhard Nieswandt Medicament for the protection against thrombotic diseases

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
GNATENKO DMITRI V ET AL: "Recent advances in platelet transcriptomics", TRANSFUSION MEDICINE AND HEMOTHERAPY, vol. 33, no. 3, June 2006 (2006-06-01), pages 217 - 226, XP009105658, ISSN: 1660-3796 *
GOH SUNG-HO ET AL: "The human reticulocyte transcriptome.", PHYSIOLOGICAL GENOMICS 18 JUL 2007, vol. 30, no. 2, 3 April 2007 (2007-04-03), pages 172 - 178, XP002497968, ISSN: 1531-2267, Retrieved from the Internet <URL:03-04-2007> [retrieved on 20070403] *
HECHLER B ET AL: "Lineage-specific overexpression of the P2Y1 receptor induces platelet hyper-reactivity in transgenic mice", JOURNAL OF THROMBOSIS AND HAEMOSTASIS, BLACKWELL PUBLISHING, OXFORD, GB, vol. 1, no. 1, 3 January 2003 (2003-01-03), pages 155 - 163, XP009105619, ISSN: 1538-7933 *
HILLMANN A G ET AL: "Comparative RNA expression analyses from small-scale, single-donor platelet samples.", JOURNAL OF THROMBOSIS AND HAEMOSTASIS : JTH FEB 2006, vol. 4, no. 2, February 2006 (2006-02-01), pages 349 - 356, XP009105673, ISSN: 1538-7933 *
MACAULAY IAIN C ET AL: "Platelet genomics and proteomics in human health and disease.", THE JOURNAL OF CLINICAL INVESTIGATION DEC 2005, vol. 115, no. 12, December 2005 (2005-12-01), pages 3370 - 3377, XP002496665, ISSN: 0021-9738 *
MILLER DAVID T ET AL: "Atherosclerosis: the path from genomics to therapeutics.", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 17 APR 2007, vol. 49, no. 15, 17 April 2007 (2007-04-17), pages 1589 - 1599, XP002496666, ISSN: 1558-3597 *
OUWEHAND W H: "Platelet genomics and the risk of atherothrombosis", JOURNAL OF THROMBOSIS AND HAEMOSTASIS, BLACKWELL PUBLISHING, OXFORD, GB, vol. 5, no. suppl. 1, 9 July 2007 (2007-07-09), pages 188 - 195, XP009105606, ISSN: 1538-7933, Retrieved from the Internet <URL:2007-07-09> [retrieved on 20070709] *
ROGER SÉVERINE ET AL: "Costimulation of the Gi-coupled ADP receptor and the Gq-coupled TXA2 receptor is required for ERK2 activation in collagen-induced platelet aggregation.", FEBS LETTERS 2 JAN 2004, vol. 556, no. 1-3, 2 January 2004 (2004-01-02), pages 227 - 235, XP004483235, ISSN: 0014-5793 *
WATSON S P ET AL: "Collagen receptor signalling in platelets: extending the role of the ITAM.", IMMUNOLOGY TODAY JUN 1998, vol. 19, no. 6, June 1998 (1998-06-01), pages 260 - 264, XP004121054, ISSN: 0167-5699 *

Also Published As

Publication number Publication date
GB0713363D0 (en) 2007-08-22
WO2009007724A2 (en) 2009-01-15

Similar Documents

Publication Publication Date Title
WO2008122670A3 (en) Human diabetes susceptibility tnfrsf10b gene
DE602006011896D1 (en) DIAGNOSTIC PROCEDURE FOR DISEASES ASSOCIATED WITH BRAIN DAMAGE
WO2005114190A3 (en) Methods of identifying biomarkers
DK1421215T3 (en) Methods for evaluating pathological conditions using extracellular RNA
WO2007126758A3 (en) Method and system for determining whether a drug will be effective on a patient with a disease
EP2503338A3 (en) CD73 as a biomarker for monitoring development of diseases and assessing the efficacy of therapies
WO2009090553A3 (en) Compositions and methods of detecting post-stop peptides
WO2006127861A3 (en) Diagnosis of diseases and conditions by analysis of histopathologically processed biological samples using liquid tissue preparations
WO2008060777A3 (en) Elisa for vegf
WO2010041046A3 (en) Granin proteins as markers of heart disease
WO2006073682A3 (en) Diagnostic test
MX382244B (en) Methods for detecting signatures of disease or conditions in bodily fluids
WO2006086442A3 (en) Method of detecting abnormal tissue
EP2365335A3 (en) Diagnostic method
WO2010084327A3 (en) Methods
WO2003062792A3 (en) Methods for determining drug responsiveness
WO2016205828A3 (en) Role of citrullination in diagnosing diseases
WO2009133197A3 (en) Levels of april in serum and use in diagnostic methods
WO2006133287A3 (en) Expression profiles of peripheral blood mononuclear cells for inflammatory bowel diseases
WO2006015874B1 (en) Method for diagnosing liver fibrosis
WO2017165766A3 (en) Biomarkers of proteopathies and uses thereof
WO2007109733A3 (en) Diagnostic and prognostic markers and treatment strategies for multiple sclerosis
WO2007015113A3 (en) New protein isoforms of the pif-family and uses thereof
WO2011062782A3 (en) Innovative blood platelets biomarker for early diagnosis of alzheimer&#39;s disease
WO2005118403A3 (en) Methods for detecting gene expression in peripheral blood cells and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08775905

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08775905

Country of ref document: EP

Kind code of ref document: A2